Expanded Germline Testing Reveals Clinically Relevant Overlap Across Hereditary Cancer Syndromes
Medical Sciences · 16.11.2026 · 14 (7) · 790
DOI: 10.3390/medsci14070790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 16.11.2026. Verfasst von Mónica Arranz-Ledo und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regional Government of Castile & Leon.
Abstract (Originalsprache)
Background
Despite the widespread implementation of BRCA1 and BRCA2 and mismatch repair testing, a substantial proportion of patients with suspected hereditary cancer remain without a molecular diagnosis. We evaluated the clinical utility of expanded germline testing in individuals with hereditary breast, ovarian and colorectal cancer susceptibility.
Methods
Patients with suspected hereditary breast, ovarian, and colorectal cancer syndromes underwent multigene panel testing using the Ion S5™ System. Pathogenic and likely pathogenic variants were correlated with clinical and histopathological features.
Results
Expanded germline testing identified clinically actionable pathogenic variants beyond BRCA1/2 and mismatch repair genes in 13% (146/1126) of high-risk families. Homologous recombination repair genes represented the largest subgroup of findings, with ATM emerging as the most prevalent non-BRCA susceptibility gene (3.7%). Among individuals fulfilling hereditary breast and ovarian cancer criteria, pathogenic variants in Lynch syndrome and polyposis genes were detected in 1.6% of cases, highlighting the limitations of phenotype-driven testing strategies. Additional pathogenic variants were identified in TP53, CDH1, CDKN2A, FANCM, NF1 and NBN, while concurrent mutations were detected in 1.15% of families.
Conclusions
These findings demonstrate that a clinically relevant proportion of hereditary cancer susceptibility lies outside the classical BRCA1/2 and mismatch repair gene framework. Incorporating non-canonical susceptibility genes into routine testing increases diagnostic yield, identifies actionable cancer risk alleles and may refine surveillance, prevention and personalised management strategies in high-risk individuals.
Förderung
- Regional Government of Castile & Leon
Zitieren
APA
Arranz-Ledo, M., Lastra, E., Gutiérrez, C., Olaverri, A., Mateo, L. C., Ferreira, R., Hernández, L., Martínez, N., Infante, M., & Durán, M. (2026). Expanded Germline Testing Reveals Clinically Relevant Overlap Across Hereditary Cancer Syndromes. Medical Sciences, 14(7), 790. https://doi.org/10.3390/medsci14070790
Vancouver
Arranz-Ledo M, Lastra E, Gutiérrez C, Olaverri A, Mateo LC, Ferreira R, et al. Expanded Germline Testing Reveals Clinically Relevant Overlap Across Hereditary Cancer Syndromes. Medical Sciences. 2026;14(7):790. doi:10.3390/medsci14070790
BibTeX
@article{ArranzLedo2026,
author = {Arranz-Ledo, Mónica and Lastra, Enrique and Gutiérrez, César and Olaverri, Amaya and Mateo, Lucia C. and Ferreira, Raquel and Hernández, Lara and Martínez, Noemí and Infante, Mar and Durán, Mercedes},
title = {Expanded Germline Testing Reveals Clinically Relevant Overlap Across Hereditary Cancer Syndromes},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {7},
pages = {790},
doi = {10.3390/medsci14070790}
}
EUVIMED